"This book provides a current review of the field of biopharmaceutical pharmacology. Biopharmaceuticals are drugs obtained in biotechnological processes using living organisms such as bacteria and fungi. An analysis was performed from biochemical and physiological point of view. This book covers an essential guide to current knowledge and analysis of biopharmaceuticals (Chapter 1-5). The composition of the biopharmaceuticals is provided. In this book we also discuss the historical point of view of the use of archeological botany, medicinal plants, strategies and main advances in communication between the nature and the advances of biopharmacy (Chapter 6-8). This book reports results from experimental and clinical work (Chapter 9). The book includes data regarding the therapy in combination with chemotherapeutic agents"--
Author(s): David Aebisher
Series: Biochemistry Research Trends
Publisher: Nova Science Publishers
Year: 2020
Language: English
Pages: 218
City: New York
Contents
Preface
Chapter 1
Biopharmaceuticals from Microorganism during 11 Years between 2019-2008
Abstract
Acknowledgments
References
Chapter 2
Bioconversion in Pharmacy
Abstract
Acknowledgments
References
Chapter 3
Biopharmaceuticals: A Selected Biological Class of Medications
Abstract
Acknowledgments
References
Chapter 4
Biopharmaceuticals and Biotechnology
Abstract
Acknowledgments
References
Chapter 5
Biopharmaceuticals: Perspectives
Abstract
Acknowledgments
References
Chapter 6
Medicinal Plants as an Aid to Archaeological Sites
Abstract
Acknowledgment
References
Chapter 7
Archeology and Botany
Acknowledgments
References
Chapter 8
Papaver Somniferum and Archeology
Acknowledgments
References
Chapter 9
Tumor Necrosis Factor Inhibitors in Clinical Practice
Biologic Drugs
TNF Antagonists Drugs
Overview of the Different TNF-Α Inhibitors
Infliximab
Adalimumab
Etanercept
Certolizumab Pegol
Golimumab
Side Effects
Conclusion
Acknowledgments
References
Chapter 10
Host Cell Protein Analysis Strategy in Biologics Manufacturing: Analysis and Control of Process-Related Impurities
Abstract
Abbreviations
Introduction
1. HCP Detection in Biopharmaceuticals
Increased Regulatory Focus on HCP Proces-Related Impurities
2. HCP Assays
Selecting a Relevant HCP-ELISA for the Process
Coverage Analysis Methods
2D-PAGE and Western Blotting
Immunoaffinity Purification and 2D-PAGE (2D-DIGE)
ELISA-Based Immunocapture Followed by LC-MS/MS (ELISA-MS)
Selecting a Relevant HCP-ELISA for E. Coli Proteins Expressed in Inclusion Bodies
Selecting a Relevant LC-MS Analysis for HCP
Reproducible Quantitation by Data Independent Acquisition LC-MS
3. Purification Process Development and Control of HCP Clearance
4. Control of Drug Substance Purity and Risk Assesment
The Benefits of Combining ELISA with LC-MS for Controlling HCP Impurities
References
About the Editor
Index
Blank Page
